Daijiworld Media Network – New Delhi

New Delhi, May 27: A small clinical case series has found that suzetrigine, a selective NaV1.8 sodium channel inhibitor developed as a non-opioid pain therapy, showed little meaningful benefit in managing severe cancer-related bone pain in patients with advanced metastatic disease.

The findings involved three male patients suffering from metastatic cancers affecting the spine and surrounding bones, all of whom had persistent pain despite undergoing multiple conventional treatments.

Researchers noted that each patient had extensive treatment histories and was already receiving opioid-based pain management before suzetrigine was introduced.

The first patient, a man in his 70s with metastatic prostate cancer involving the spine and ilium, reportedly continued to experience severe pain despite earlier treatment with NSAIDs and gabapentinoids. He was receiving hydrocodone therapy equivalent to around 30 morphine milligram equivalents daily. After a three-week course of suzetrigine, he reported little to no improvement, leading to discontinuation of the medication due to lack of effectiveness and high cost.

The second patient, a man in his 60s with metastatic lung cancer affecting the spine and brain, was already being treated with NSAIDs, gabapentinoids and duloxetine, in addition to opioid medications including fentanyl patches and hydrocodone. Despite adding suzetrigine as adjunctive therapy, no significant pain relief was observed after three weeks. The patient later entered hospice care as his illness progressed.

The third patient, also in his 60s and suffering from metastatic prostate cancer involving the spine and ilium, similarly reported only minimal pain improvement after the trial period and eventually stopped treatment.

Researchers noted that none of the patients experienced major adverse effects, indicating that the drug appeared to have a favourable short-term safety profile. However, the absence of significant pain reduction raised concerns regarding its effectiveness in advanced metastatic bone pain cases.

The report suggested that targeting the NaV1.8 sodium channel alone may not be sufficient in managing complex cancer-related bone pain, which often involves inflammation, bone destruction, nerve compression and central nervous system sensitisation.

The authors also highlighted that opioid tolerance and rapid disease progression could reduce the likelihood of observing meaningful benefit from newer non-opioid therapies in advanced-stage patients.

Researchers have now called for larger randomised clinical trials to evaluate whether suzetrigine may show greater effectiveness in patients with earlier-stage disease, alternative dosing approaches or among opioid-naïve individuals.